Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $1.43B |
| Gross Profit (TTM) | $916.19M |
| EBITDA | $-193.36M |
| Operating Margin | -20.10% |
| Return on Equity | -67.40% |
| Return on Assets | -8.55% |
| Revenue/Share (TTM) | $8.05 |
| Book Value | $2.47 |
| Price-to-Book | 31.25 |
| Price-to-Sales (TTM) | 10.71 |
| EV/Revenue | 10.15 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 21.60% |
| Shares Outstanding | $175.39M |
| Float | $116.06M |
| % Insiders | 36.77% |
| % Institutions | 59.28% |
Volatility is currently contracting
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
Tempus AI remains a Buy as I increase my position, driven by strategic moves and accelerating growth. TEM's acquisition of Personalis fills a critical MRD monitoring gap, unlocking recurring revenue and enhancing AI data assets. Q2 2026 saw 22% revenue growth, improved margins, and raised full-year guidance, despite continued operating losses.
Tempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding data & applications revenue. Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly doubling since Q4 2025, validating the Personalis acquisition. Data & applications segment led Q2 growth at 28%, with strong bookings and AI innovation positioning the company for long-term growth and margin expansion.
Tempus AI NASDAQ: TEM Founder and CEO Eric Lefkofsky said the company's second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business.
Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization above $14 billion.
Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tempus AI (NASDAQ:TEM | TEM Price Prediction) is having a breakout week after Morgan Stanley remarks on September 15 spotlighted fresh reimbursement-driven revenue lifts for the AI-powered diagnostics company. Shares have rallied 29.
Tempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TEM and any ticker you trade — then tracks every position and per-strategy win rate.
